Corcept Therapeutics (CORT) Climbs 19.7% as Lifyorli Gets FDA OK.
Share this article
Corporate
Score 85
Bullish
Corcept Therapeutics (CORT) Climbs 19.7% as Lifyorli Gets FDA OK
Mar 26, 2026 01:01 UTC
CORT, XLV, IBB
Short term
Related Articles
Score 85
Bullish
AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed
Mar 27, 12:54
Score 35
American Airlines Weighs Bringing Back Seatback Screens in Narrow-Body Fleet Revamp
Mar 27, 12:53
Score 85
Bullish
SoftBank Secures Record $40 Billion Bridge Loan for OpenAI Stake
Mar 27, 11:48
Score 85
Bullish
Novartis Acquires Excellergy for $2 Billion in Latest Biotech M&A Push
Mar 27, 11:43
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.